Related Experiment Videos
Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective,
Andrés Martin1, Kathleen Koenig, George M Anderson
1Child Study Center, Yale University, New Haven, Connecticut 06520-7900, USA. Andres.Martin@Yale.Edu
Abstract:
The objective of this study was to assess the efficacy and tolerability of low-dose fluvoxamine (1.5 mg/kg/day) in youngsters with pervasive developmental disorders (PDDs). This was a prospective, open-label trial that included 18 subjects with a mean age of 11.3 +/- 3.6 years. Fourteen children (78%) completed the 10-week study. Premature discontinuation due to behavioral activation occurred in three participants. Although there was no response for the group as a whole, eight subjects (including all four females) were considered at least partial responders in intent-to-treat analyses. Neither pubertal status nor serotonin levels predicted clinical response. Fluvoxamine can be beneficial in the treatment of select children and adolescents with PDDs. Gender differences in selective serotonin reuptake inhibitor (SSRI) response warrant further investigation.
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Drug Dosing: Infants and Children
Oppositional Defiant Disorder
Diagnostic Criteria and...
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Antidepressant Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents